Imaging biomarker distinguishes prostate cancer tumor grade

Posted by on June 1, 2016 5:18 pm
Categories: health

Physicians have long used magnetic resonance imaging (MRI) to detect cancer, but results of a new study describe the potential use of restriction spectrum imaging (RSI) as an imaging biomarker that enhances the ability of MRI to differentiate aggressive prostate cancer from low-grade or benign tumors and guide treatment and biopsy.

Leave a Reply

Your email address will not be published. Required fields are marked *